A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 26 Jan 2018 Planned End Date changed from 18 Nov 2020 to 28 Oct 2020.
- 26 Jan 2018 Planned primary completion date changed from 19 Nov 2019 to 29 Oct 2019.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.